Product Description
intranasal morphine (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00474799)
Mechanisms of Action: OPR Binder
Novel Mechanism: Yes
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hospira
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Morphine Dependence
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00474799 |
Intranasal Morphine | P1 |
Completed |
Morphine Dependence |
2007-02-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/21/2019 |
News Article |
Hallux Valgus Pipeline Insights, 2019 Report - Overview of Therapeutic Pipeline Activity - ResearchAndMarkets.com |